This paper reviews drugs for chronic hepatitis B, noting that the only FDA‑approved medicines right now are interferon‑alpha‑2b and lamivudine. It lists many newer compounds being studied, including thymosin‑alpha‑1, which is still experimental and not yet available for regular use. For biohackers, the key point is that thymosin‑alpha‑1 may become a future option, but there’s no proven dosing or protocol to try today.

Hepatitis B, a major viral infection that can lead to cirrhosis and hepatocellular carcinoma, is the ninth most common cause of death worldwide. Prevention of hepatitis B virus transmission is key to reducing the spread of this serious condition. Management of chronic hepatitis B requires significant knowledge of approved pharmacotherapeutic agents and their limitations. Today, agents approved by the Food and Drug Administration for this infection are interferon-alpha-2b and lamivudine. Newer agents are being developed and hold promise: adefovir, famciclovir, ganciclovir, lobucavir, entecavir, emtricitabine, L-deoxythymidine, clevudine, a therapeutic vaccine, and thymosin alpha-1. Therapeutic options for managing hepatitis infection after liver transplantation are also evolving. These include hepatitis B immunoglobulin and nucleoside analogues.